Barrington Maintains SurModics(SRDX.US) With Hold Rating
Surmodics Analyst Ratings
Needham Maintains SurModics(SRDX.US) With Hold Rating
Barrington Maintains SurModics(SRDX.US) With Hold Rating
SurModics Holds Steady Amid Acquisition Uncertainty: A Market Perform Rating
Lake Street Maintains SurModics(SRDX.US) With Hold Rating, Maintains Target Price $43
SurModics (SRDX) Receives a Hold From Lake Street
SurModics (SRDX) Was Downgraded to a Hold Rating at Barrington
Sidoti & Co. Downgrades Surmodics to Neutral, Announces $43 Price Target
Sidoti & Co. : The Surmodics (SRDX.US) rating was downgraded from buying to neutral, and the target price was $43.00.
Surmodics Analyst Ratings
SurModics (SRDX) Was Downgraded to a Hold Rating at Needham
SurModics (SRDX) Gets a Buy From Lake Street
Analysts Are Bullish on These Healthcare Stocks: Assertio Therapeutics (ASRT), SurModics (SRDX)
Barrington Research: Maintaining the Surmodics (SRDX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $71.00 to $71.00.
Surmodics Analyst Ratings
Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
Needham: Maintaining the Surmodics (SRDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $47.00 to $43.00.
Surmodics Analyst Ratings